Sarcopenia definition, diagnosis and treatment: consensus is growing
2022/10/01 by Avan Aihie Sayer, Alfonso Cruz-Jentoft, Alfonso J. Cruz‐Jentoft · 30 citations
Medicine · #Nutrition and Health in Aging #Cerebral Palsy and Movement Disorders #Body Composition Measurement Techniques
paper · pdf · doi:10.1093/ageing/afac220
Abstract
Sarcopenia is a skeletal muscle disorder that commonly occurs with advancing age as well as with a number of long-term conditions. Recognition in clinical practice is relatively recent but important because of the association between sarcopenia and a range of adverse effects on health including impaired mobility, increased morbidity and mortality. Originally characterised as loss of muscle mass, the definition has evolved to focus on loss of skeletal muscle function, particularly strength, through a number of international definitions such as that of the European Working Group on Sarcopenia in Older People most recently revised in 2019. Progress in the decades ahead is likely to be seen with regard to use of routine health data, prescription of resistance exercise, translation of biology and epidemiology into first in man studies for new treatments, and focus on sarcopenia in low and middle-income countries. Immediate next steps include the newly formed Global Leadership Initiative on Sarcopenia to develop international consensus on definition and diagnosis.
Citations
Cited by
- Association between sarcopenic obesity and risk of frailty in older adults: a systematic review and meta-analysis
- Ageing of human myofibres in the Vastus Lateralis muscle: A narrative review
- Improving sarcopenia in older adults: a systematic review and meta-analysis of randomized controlled trials of whey protein supplementation with or without resistance training
- Addressing undernutrition in older adults with plant-based products
- Associations of Creatinine Muscle Index with markers of sarcopenia and mortality in chronic kidney disease: A prospective cohort study
- Insights into Pathogenesis, Nutritional and Drug Approach in Sarcopenia: A Systematic Review. [europepmc]
- Dietary phosphate restriction prevents the appearance of sarcopenia signs in old mice. [europepmc]
- Associations between the muscle quality index and adult lung functions from NHANES 2011-2012. [europepmc]
- Accounting Gut Microbiota as the Mediator of Beneficial Effects of Dietary (Poly)phenols on Skeletal Muscle in Aging. [europepmc]
- Investigating association between gut microbiota and sarcopenia-related traits: a Mendelian randomization study. [europepmc]
- Inflammatory biomarkers at different stages of Sarcopenia in older women. [europepmc]
- Pathogenesis, Intervention, and Current Status of Drug Development for Sarcopenia: A Review. [europepmc]
- The prevalence of sarcopenia in Parkinson's disease and related disorders- a systematic review. [europepmc]
- Genetic Variants, Serum 25-Hydroxyvitamin D Levels, and Sarcopenia: A Mendelian Randomization Analysis. [europepmc]
- The role of nutrition in the prevention of sarcopenia. [europepmc]
- A Bidirectional Mendelian Randomization Study of Sarcopenia-Related Traits and Knee Osteoarthritis. [europepmc]
- Bifidobacterium bifidum and Lactobacillus paracasei alleviate sarcopenia and cognitive impairment in aged mice by regulating gut microbiota-mediated AKT, NF-κB, and FOXO3a signaling pathways. [europepmc]
- Comparing associations of handgrip strength and chair stand performance with all-cause mortality-implications for defining probable sarcopenia: the Tromsø Study 2015-2020. [europepmc]
- Higher systemic immune-inflammation index is associated with sarcopenia in individuals aged 18-59 years: a population-based study. [europepmc]
- Improving sarcopenia in older adults: a systematic review and meta-analysis of randomized controlled trials of whey protein supplementation with or without resistance training. [europepmc]
- Obstacles to the Early Diagnosis and Management of Sarcopenia: Current Perspectives. [europepmc]
- Effect of gut microbiome modulation on muscle function and cognition: the PROMOTe randomised controlled trial. [europepmc]
- Associations of physical activity intensity, frequency, duration, and volume with the incidence of sarcopenia in middle-aged and older adults: a 4-year longitudinal study in China. [europepmc]
- Systemic immune-inflammation index and all-cause and cause-specific mortality in sarcopenia: a study from National Health and Nutrition Examination Survey 1999-2018. [europepmc]
- Associations of CBC-Derived inflammatory indicators with sarcopenia and mortality in adults: evidence from Nhanes 1999 ∼ 2006. [europepmc]
- Omega-3 polyunsatured fatty acids and physical performance across the lifespan: a narrative review. [europepmc]
- The prevalence of sarcopenia and risk factors in the older adult in China: a systematic review and meta-analysis. [europepmc]
- The ZJU index is associated with the risk of sarcopenia in American adults aged 20-59: a cross-sectional study. [europepmc]
- Exploring the Relationship Between Gut Microbiota and Sarcopenia Based on Gut-Muscle Axis. [europepmc]
- Gut microbiota in patients with sarcopenia: a systematic review and meta-analysis. [europepmc]
Related